• Wenliang Zhai, Zujin Luo, Yue Zheng, Dawei Dong, Endong Wu, Zhengfang Wang, Junpeng Zhai, Yujuan Han, Huan Liu, Yanran Wang, Yaohui Feng, Jing Wang, and Yingmin Ma.
• Department of Emergency, Xuanwu Hospital, Capital Medical University, No.45 Changchunjie Street, Xicheng District, Beijing, 100053, China.
• Sci Rep. 2021 Mar 22; 11 (1): 6483.

AbstractThis study compared the differences in the clinical manifestations, treatment courses and clinical turnover between mild and moderate coronavirus disease 2019 (COVID-19). Clinical data of the patients with imported COVID-19 admitted to Beijing Xiaotangshan Designated Hospital between March 15 and April 30, 2020, were retrospectively analysed. A total of 53 COVID-19 patients were included, with 21 mild and 32 moderate cases. Compared with the mild group, the moderate group showed significant differences in breathing frequency, lymphocyte count, neutrophil percentage, neutrophil/lymphocyte ratio, procalcitonin, C-reactive protein, and dynamic erythrocyte sedimentation rate. In the moderate group, 87.5% exhibited ground-glass opacities, 14% exhibited consolidative opacities, 53.1% exhibited local lesions and 68.8% exhibited unilateral lesions. The proportion of patients who received antiviral or antibiotic treatment in the moderate group was higher than that in the mild group, and the number of cases that progressed to severe disease in the moderate group was also significantly higher (18.7% vs. 0%, p = 0.035). Compared with patients with mild COVID-19, those with moderate COVID-19 exhibited more noticeable inflammatory reactions, more severe pulmonary imaging manifestations and earlier expression of protective antibodies. The overall turnover of the moderate cases was poorer than that of the mild cases.

31 keywords...

hide…